Tempest Therapeutics Inc.

TPST | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.80

+$0.03 (+3.39%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.39%

(1D)

Rating

Updated: Aug 18, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $12.75M

1D Range

0.77 0.80

52W Range

0.74 12.23

Valuation (TTM)

PE -0.17

PB -11.34

EV/EBITDA -0.48

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target $11

Cash Flow

FCF Yield -167.7%

SBC Adj. FCF Yield -173.7%

SBC Impact -3.6%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -35.2% | -9.6%

FCF 3Y | 5Y 9.1% | 7.8%

Returns

ROA -420.1%

ROE -1270.1%

ROIC -628.2%

Financial Health

Net Debt

$6.78M

Current Ratio 0.38

Interest Coverage -1,767.09

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highligh...

Sector Healthcare

Industry Biotechnology

Employees 4

IPO Date Nov 11, 2012

Website www.tempesttx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$11

Upside

+1275.00%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞